Samrat Pharmachem reported a return to profitability in its standalone results for the first quarter of FY27, posting a net profit of ₹87.60 lakh for the period ended June 30, 2026. This marks a significant turnaround from the previous quarter, where the company recorded a net loss of ₹203.63 lakh.

The pharmaceutical chemicals manufacturer saw its total income from operations rise to ₹7,976.10 lakh in Q1FY27, up from ₹7,565.16 lakh in the same period last year. The improvement in top-line performance helped the company generate a profit before tax of ₹158.53 lakh, compared to a pre-tax loss of ₹187.33 lakh in Q4FY26.

Financial Performance

The company’s financial metrics for the quarter and the preceding periods are detailed below:

For the full fiscal year ended March 31, 2025, Samrat Pharmachem reported a net loss of ₹331.20 lakh on total income of ₹28,972.12 lakh. The basic earnings per share for Q1FY27 stood at ₹2.84, improving from a loss of ₹6.59 per share in the previous quarter.

What the Numbers Show

The divergence between revenue growth and profit realization highlights the volatility in the company's operational efficiency during this period. While revenue grew modestly by approximately 5.4% year-on-year, the shift from a pre-tax loss of ₹187.33 lakh in Q4FY26 to a pre-tax profit of ₹158.53 lakh in Q1FY27 indicates a sharp correction in cost management or pricing dynamics. However, with no exceptional items disclosed, the entire profit reversal is attributable to core operational improvements rather than one-off gains.

The Board of Directors approved the unaudited standalone financial results in a meeting held on August 14, 2026, at the company’s corporate office in Mumbai. The results were reviewed by the Audit Committee prior to board approval.

Samrat Pharmachem Limited has appointed Divyesh J Shah & Associates as its statutory auditors for a term of five years, subject to the approval of shareholders. The decision was taken by the Board of Directors at its meeting held on July 15, 2026, following the recommendation of the Audit Committee of Directors. The appointment is effective from the conclusion of the 34th Annual General Meeting and will remain in force until the conclusion of the 39th Annual General Meeting.

The disclosure was made to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation detailed that the firm, with ICAI Firm Registration No. 118227W, will serve as the statutory auditors for the specified duration. The Board meeting, which commenced at 2.00 p.m. and concluded at 3.30 p.m. IST, approved the appointment to ensure continued audit oversight.

Divyesh J Shah & Associates, established in 1998, is a partnership firm registered at 410, Parmeshwari Centre, MMM Road, 80, Mulund (West), Mumbai - 400080. The firm offers professional services including auditing, taxation, and management consultancy to clients across India. Its profile indicates prior experience in statutory bank branch audits, debt syndication, and due diligence for mergers and acquisitions. The firm was also appointed by the Government of Maharashtra in 2012 for state subsidy policy guidance.

The appointment is subject to ratification by the members of the company. The information regarding the new auditors has been made available on the company's official website. The company secretary, Nishant Kankaria, signed the disclosure on July 17, 2026, confirming the Board's decision.

Details of Appointment